Antiproteinuric effect of KD3-671, an angiotensin II type 1 receptor antagonist, in rats with accelerated passive Heymann nephritis.
The antiproteinuric effect of KD3-671 (2-propyl-8-oxo-1-[(2'-(H-tetrazole-5-yl)biphenyl-4-yl)methyl]-4,5,6,7-tetrahydrocycloheptimidazole), an angiotensin II type 1 receptor antagonist, was compared with that of enalapril, an angiotensin 11-converting enzyme inhibitor, using an experimental model of membranous nephropathy. KD3-671 (3, 10 and 30 mg/kg per day) and enalapril (30 mg/kg per day) were given p.o. for 40 days, respectively. KD3-671 (30 mg/kg per day) inhibited the elevation of proteinuria and plasma total cholesterol. On the other hand, enalapril showed only a tendency to diminish these parameters. KD3-671 had an antiproteinuric effect in rats with accelerated passive Heymann nephritis. These findings provide considerable encouragement for the clinical development of KD3-671.
Nagamatsu
Tadashi
T
Department of Pharmacology, Faculty of Pharmacy, Meijo University, Nagoya, Japan. nagamats@meijo-u.ac.jp
Nagao
Toshiyuki
T
Hayashi
Kazumi
K
Suzuki
Yoshio
Y
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000097:blood / Q000627:therapeutic use; D000818:Animals; D001806:Blood Urea Nitrogen; D002784:Cholesterol / Q000097:blood; D004656:Enalapril / Q000097:blood / Q000627:therapeutic use; D005921:Glomerulonephritis / Q000188:drug therapy*; D007093:Imidazoles / Q000097:blood / Q000737:chemistry / Q000627:therapeutic use*; D008297:Male; D011507:Proteinuria / Q000188:drug therapy; D051381:Rats; D017207:Rats, Sprague-Dawley; D013777:Tetrazoles / Q000097:blood / Q000737:chemistry / Q000627:therapeutic use*
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D007093:Imidazoles; C121117:KD3 671; D013777:Tetrazoles; D004656:Enalapril; D002784:Cholesterol